Dacarbazine Powder for Injection 200 mg

๐Ÿ’Š Medicine Name:

Dacarbazine

๐Ÿ’‰ Formulation:

Powder for Injection (lyophilized) โ€“ for intravenous (IV) administration

๐Ÿ’ช Strength:

200 mg per vial


๐Ÿ“œ Description:

Dacarbazine is a cytotoxic antineoplastic agent used mainly in the treatment of malignant melanoma and Hodgkin lymphoma. It functions as an alkylating agent, although it is technically a prodrug that requires activation in the liver.


๐ŸŒฟ Nature:

  • Alkylating-like agent (triazene group)
  • Cell cycle-nonspecific, but most effective against rapidly dividing cells
  • Classified as a cytotoxic chemotherapy drug
  • Typically used in combination regimens (e.g., ABVD for Hodgkin lymphoma)

๐ŸŒŸ Advantages:

  • Key component of the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) โ€“ a gold-standard treatment for Hodgkin lymphoma
  • Also effective as monotherapy in metastatic malignant melanoma
  • Available in multiple strengths (e.g., 100 mg, 200 mg) for dosing flexibility
  • Long history of clinical use with predictable toxicity profile
  • Can be used in both curative and palliative oncology settings

๐Ÿงพ Prescription:

  • Prescription-only drug (Rx)
  • Should only be administered under the supervision of qualified oncologists in hospitals or chemotherapy centers

๐ŸŽฏ Indications / Uses:

  • Hodgkin lymphoma (in combination therapy)
  • Metastatic malignant melanoma
  • Also used off-label for soft tissue sarcomas and neuroendocrine tumors in selected protocols

๐Ÿ“ฆ Packaging:

  • Supplied as a sterile lyophilized powder in glass vials
  • Reconstituted with sterile water before dilution in IV fluids
  • Requires cytotoxic precautions during handling and administration

๐ŸงŠ Storage:

  • Store unopened vials at 15โ€“25ยฐC (room temperature)
  • Protect from light and moisture
  • Use reconstituted solution within the recommended timeframe per product guidelines
  • Do not freeze the solution

๐Ÿ‘จโ€โš•๏ธ Patient Advice:

  • Administered only in medical facilities with proper safety monitoring
  • Patients must undergo frequent blood monitoring
  • Avoid exposure to infections due to temporary immune suppression
  • May require pre-medications to manage nausea and vomiting
  • Inform the doctor of any neurological symptoms or persistent vomiting

Leave a Comment

Your email address will not be published. Required fields are marked *

Call Now Button